---
stable_id: R-HSA-2033474
display_name: FGFR2b mutants bind an expanded range of ligands
species: Homo sapiens
summary: Apert sydrome is the most severe of the craniosynostosis syndromes and results
  almost entirely from two missense mutations in the conserved Ser252 and Pro253 residues
  in the IgII-IgIII linker of FGFR2 (Wilkie, 1995). These mutations affect both the
  'b' and 'c' isoforms, although mutation in the FGFR2c isoform is believed to be
  more clinically relevant to the development of Apert syndrome (Lomri, 1998).  More
  recently, the same mutations arising somatically have been identified in endometrial
  and ovarian cancer (Dutt, 2008; Byron, 2008; Pollock, 2007).<br><br><br>The IgII
  and IgIII domains and the intervening linker of the FGF receptor constitute a binding
  site for FGFs (Chellaiah, 1999; Stauber, 2000; Plotnikov, 1999).   The epithelial
  isoform FGFR2b binds only to mesenchymally expressed ligands including FGF7 and
  FGF10 and does not respond to epithelial ligands FGF2, 4, 6, 8 and 9 (Ornitz, 1996).  Introduction
  of the P252W and P252R mutations into FGFR2b allows the aberrant binding and activation
  by the epithelially expressed ligands FGF 2, 6 and 9, establishing an autocrine
  signaling loop in epithelial cells.  These mutations also increase the binding affinity
  for the receptor's normal mesenchymal ligands 2- to 8-fold  (Yu, 2000; Ibrahimi,
  2004b).  Based on biochemical and crystal studies, the mutations in the IgII-IgIII
  linker region are predicted to alter the hydrogen bonding network in this region
  and may change the conformation and thus the ligand-binding properties of the mutant
  receptors (Stauber, 2000).<br>
---

# FGFR2b mutants bind an expanded range of ligands
**Reactome ID:** [R-HSA-2033474](https://reactome.org/content/detail/R-HSA-2033474)
**Species:** Homo sapiens

## Summary

Apert sydrome is the most severe of the craniosynostosis syndromes and results almost entirely from two missense mutations in the conserved Ser252 and Pro253 residues in the IgII-IgIII linker of FGFR2 (Wilkie, 1995). These mutations affect both the 'b' and 'c' isoforms, although mutation in the FGFR2c isoform is believed to be more clinically relevant to the development of Apert syndrome (Lomri, 1998).  More recently, the same mutations arising somatically have been identified in endometrial and ovarian cancer (Dutt, 2008; Byron, 2008; Pollock, 2007).<br><br><br>The IgII and IgIII domains and the intervening linker of the FGF receptor constitute a binding site for FGFs (Chellaiah, 1999; Stauber, 2000; Plotnikov, 1999).   The epithelial isoform FGFR2b binds only to mesenchymally expressed ligands including FGF7 and FGF10 and does not respond to epithelial ligands FGF2, 4, 6, 8 and 9 (Ornitz, 1996).  Introduction of the P252W and P252R mutations into FGFR2b allows the aberrant binding and activation by the epithelially expressed ligands FGF 2, 6 and 9, establishing an autocrine signaling loop in epithelial cells.  These mutations also increase the binding affinity for the receptor's normal mesenchymal ligands 2- to 8-fold  (Yu, 2000; Ibrahimi, 2004b).  Based on biochemical and crystal studies, the mutations in the IgII-IgIII linker region are predicted to alter the hydrogen bonding network in this region and may change the conformation and thus the ligand-binding properties of the mutant receptors (Stauber, 2000).<br>
